Research graph
References from The role of <scp>PSA</scp> density in the follow up of men with a negative <scp>MRI</scp> in the Göteborg‐2 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Results after four years of screening for prostate cancer with PSA and MRI
10.1056/nejmoa2406050 · 2024 · External reference
Prostate cancer screening with PSA and MRI followed by targeted biopsy only
10.1056/nejmoa2209454 · 2022 · External reference
Repeated prostate cancer screening using prostate‐specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3‐MRI randomized clinical trial
10.1001/jamanetworkopen.2023.54577 · 2024 · External reference
Blood prostate‐specific antigen by volume of benign, Gleason pattern 3 and 4 prostate tissue
10.1016/j.urology.2022.08.014 · 2022 · External reference
The influence of prostate‐specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7‐10 prostate cancer in a repeat biopsy setting
10.1111/bju.13619 · 2017 · External reference
Prebiopsy Biparametric magnetic resonance imaging combined with prostate‐specific antigen density in detecting and ruling out Gleason 7‐10 prostate cancer in biopsy‐naïve men
10.1016/j.euo.2018.09.001 · 2019 · External reference
Risk‐adapted biopsy decision based on prostate magnetic resonance imaging and prostate‐specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
10.1111/bju.15277 · 2021 · External reference
Multiparametric magnetic resonance imaging and follow‐up to avoid prostate biopsy in 4259 men
10.1111/bju.14853 · 2019 · External reference
Outcome of 5‐year follow‐up in men with negative findings on initial biparametric MRI
10.1016/j.heliyon.2021.e08325 · 2021 · External reference
Combination of biparametric magnetic resonance imaging with prostate‐specific antigen density to stratify the risk of significant prostate cancer: initial biopsy and long‐term follow‐up results
10.1111/iju.14948 · 2022 · External reference
The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population‐based prostate cancer screening trial with prostate‐specific antigen testing followed by magnetic resonance imaging of the prostate
10.1080/21681805.2021.1881612 · 2021 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Negative multiparametric magnetic resonance imaging for prostate cancer: what's next?
10.1016/j.eururo.2018.03.007 · 2018 · External reference
Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer
10.1111/bju.14049 · 2018 · External reference
Prostate cancer screening using a combination of risk‐prediction, MRI, and targeted prostate biopsies (STHLM3‐MRI): a prospective, population‐based, randomised, open‐label, non‐inferiority trial
10.1016/s1470-2045(21)00348-x · 2021 · External reference
Performance of 4Kscore as a reflex test to prostate‐specific antigen in the GÖTEBORG‐2 prostate cancer screening trial
10.1016/j.eururo.2024.04.037 · 2024 · External reference
Prostate cancer screening with PSA, Kallikrein panel, and MRI: the ProScreen randomized trial
10.1001/jama.2024.3841 · 2024 · External reference
Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience
10.1016/j.juro.2016.06.102 · 2016 · External reference
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer
10.1016/j.juro.2013.09.034 · 2014 · External reference
Prostate‐specific antigen density as a selection tool before magnetic resonance imaging in prostate cancer screening: an analysis from the STHLM3MRI randomized clinical trial
10.1016/j.euf.2025.06.008 · 2025 · External reference
Prostate specific antigen density and clinically‐significant prostate cancer: the influence of prostatic volume
10.1002/pros.24886 · 2025 · External reference
Bi‐ or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
10.1007/s00330-021-07907-9 · 2021 · External reference
Prostate cancer screening with PSA, Kallikrein panel, and MRI: the ProScreen randomized trial
10.1001/jama.2024.3841 · ExternalCitation · doi-reference
Repeated prostate cancer screening using prostate‐specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3‐MRI randomized clinical trial
10.1001/jamanetworkopen.2023.54577 · ExternalCitation · doi-reference
Prostate specific antigen density and clinically‐significant prostate cancer: the influence of prostatic volume
10.1002/pros.24886 · ExternalCitation · doi-reference
Bi‐ or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
10.1007/s00330-021-07907-9 · ExternalCitation · doi-reference
Prostate‐specific antigen density as a selection tool before magnetic resonance imaging in prostate cancer screening: an analysis from the STHLM3MRI randomized clinical trial
10.1016/j.euf.2025.06.008 · ExternalCitation · doi-reference
Prebiopsy Biparametric magnetic resonance imaging combined with prostate‐specific antigen density in detecting and ruling out Gleason 7‐10 prostate cancer in biopsy‐naïve men
10.1016/j.euo.2018.09.001 · ExternalCitation · doi-reference
Negative multiparametric magnetic resonance imaging for prostate cancer: what's next?
10.1016/j.eururo.2018.03.007 · ExternalCitation · doi-reference
Performance of 4Kscore as a reflex test to prostate‐specific antigen in the GÖTEBORG‐2 prostate cancer screening trial
10.1016/j.eururo.2024.04.037 · ExternalCitation · doi-reference
Outcome of 5‐year follow‐up in men with negative findings on initial biparametric MRI
10.1016/j.heliyon.2021.e08325 · ExternalCitation · doi-reference
Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer
10.1016/j.juro.2013.09.034 · ExternalCitation · doi-reference
Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience
10.1016/j.juro.2016.06.102 · ExternalCitation · doi-reference
Blood prostate‐specific antigen by volume of benign, Gleason pattern 3 and 4 prostate tissue
10.1016/j.urology.2022.08.014 · ExternalCitation · doi-reference
Prostate cancer screening using a combination of risk‐prediction, MRI, and targeted prostate biopsies (STHLM3‐MRI): a prospective, population‐based, randomised, open‐label, non‐inferiority trial
10.1016/s1470-2045(21)00348-x · ExternalCitation · doi-reference
Prostate cancer screening with PSA and MRI followed by targeted biopsy only
10.1056/nejmoa2209454 · ExternalCitation · doi-reference
Results after four years of screening for prostate cancer with PSA and MRI
10.1056/nejmoa2406050 · ExternalCitation · doi-reference
The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population‐based prostate cancer screening trial with prostate‐specific antigen testing followed by magnetic resonance imaging of the prostate
10.1080/21681805.2021.1881612 · ExternalCitation · doi-reference
The influence of prostate‐specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7‐10 prostate cancer in a repeat biopsy setting
10.1111/bju.13619 · ExternalCitation · doi-reference
Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy‐naïve men with suspicion of prostate cancer
10.1111/bju.14049 · ExternalCitation · doi-reference
Multiparametric magnetic resonance imaging and follow‐up to avoid prostate biopsy in 4259 men
10.1111/bju.14853 · ExternalCitation · doi-reference
Risk‐adapted biopsy decision based on prostate magnetic resonance imaging and prostate‐specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation
10.1111/bju.15277 · ExternalCitation · doi-reference
Combination of biparametric magnetic resonance imaging with prostate‐specific antigen density to stratify the risk of significant prostate cancer: initial biopsy and long‐term follow‐up results
10.1111/iju.14948 · ExternalCitation · doi-reference
